An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.
Phase of Trial: Phase I/II
Latest Information Update: 06 Apr 2017
Price : $35 *
At a glance
- Drugs Mercaptamine (Primary)
- Indications Cystic fibrosis
- Focus First in man; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 06 Apr 2017 This trial has been discontinued in UK (End date:2015-03-06) as per European Clinical Trials Database record.
- 24 Jun 2016 According to a NovaBiotics media release, data this trial was presented at the ASM Microbe conference.